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Abstract 
Cysteine string protein (CSP) is a member of the DnaJ/Hsp40 family of co-
chaperones that localises to neuronal synaptic vesicles. Its name derives from the 
possession of a string of 12-15 cysteine residues, palmitoylation of which is required 
for targeting to post-Golgi membranes. The DnaJ domain of CSP enables it to bind 
client proteins and recruit Hsc70 chaperones, thereby contributing to the 
maintenance of protein folding in the presynaptic compartment. Mutation of CSP in 
flies, worms and mice reduces lifespan and causes synaptic dysfunction and 
neurodegeneration. Furthermore, recent studies have revealed that the 
neurodegenerative disease, adult-onset neuronal ceroid lipofuscinosis, is caused by 
mutations in the human CSPα-encoding DNAJC5 gene. Accumulating evidence 
suggests that the major mechanism by which CSP prevents neurodegeneration is by 
maintaining the conformation of SNAP-25, thereby facilitating its entry into the 
membrane-fusing SNARE complex. In this review, we focus on the role of CSP in 
preventing neurodegeneration and discuss how recent studies of this universal 
neuroprotective chaperone are being translated into potential novel therapeutics for 
neurodegenerative diseases.  
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1. Introduction: Discovery and properties of CSPs 
Cysteine string protein (CSP) was first discovered in Drosophila melanogaster based 
on the use of a neuronal-specific monoclonal antibody that labelled nerve terminals.  
Cloning of cDNA revealed that the antibody recognised proteins encoded by three 
splice variants of a novel gene. These were distinguished by the presence of a string 
of 11 contiguous cysteine residues leading to the naming of the protein(s) as 
cysteine string protein [1]. Soon after, a CSP was also discovered in Torpedo 
californica following an attempt to identify possible subunits of neuronal calcium 
channels, which at that time had not been identified or molecularly characterised [2], 
and it was shown to be localised to synaptic vesicles [3]. CSPs were soon identified 
in mammalian species [4-6]. The Torpedo protein [7] and subsequently CSPs in 
other species were found to be extensively palmitoylated on their cysteine residues. 
Palmitoylation was shown to determine the membrane association of CSPs [8-10] 
and the enzymatic basis for palmitoylation of CSP has been extensively studied [11-
16]. In addition to being expressed in multiple species, CSP was also found to be 
present on a wide range of types of secretory vesicles in neuronal and non-neuronal 
tissues [5, 6, 17-19]. Invertebrates such as Drosophila and Caenorhabditis elegans 
have only a single CSP-encoding gene (Csp and dnj-14, respectively); whereas 
mammals express three CSP proteins (α, β, γ) that are encoded by the DNAJC5a, b 
and g genes. CSPα and CSPβ are highly homologous throughout their amino acid 
sequences, but CSPγ is more distantly related [20]. CSPα is the major protein 
expressed in most cells and virtually all neurons. In contrast, mammalian CSPβ and 
CSPγ are expressed only in testis [21, 22], with the exception that CSPβ is uniquely 
also expressed in auditory hair cell neurons [23, 24]. The functional roles of CSPβ 
and CSPγ are unknown. 
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The sequence of CSP revealed that it contains a conserved J domain (Figure 
1) and so it is a member of the DnaJ/Hsp40 family of co-chaperones. CSP has a 
characteristic HPD motif in the J-domain that is required in this family of proteins to 
allow them to bind to Hsc70/Hsp70 and act in concert with Hsc70/Hsp70 in the 
refolding or disaggregation of client proteins. Biochemical analysis of CSP 
demonstrated that it could indeed bind to and activate the ATPase activity of Hsc70 
[25, 26] and also that it could reverse aggregation of model substrates in conjunction 
with Hsc70 [27]. It was subsequently suggested that CSP and Hsc70 function along 
with small glutamine-rich tetratricopeptide repeat-containing protein (SGT) in a 
trimeric complex [28, 29]. While CSP is clearly able to bind to SGT, there are doubts 
about the physiological significance of the SGT interaction. These stem from the fact 
that the interaction of SGT with CSP characterised in vitro with recombinant proteins 
and via the yeast 2-hybrid method occurs through the non-palmitoylated cysteine-
string domain [29], which would not be available for interaction in vivo. Recently it 
has been established that SGT is a chaperone for the transmembrane region of tail-
anchored proteins [30, 31], suggesting that SGT binding to recombinant CSP in vitro 
may be a consequence of  its artefactual recognition of the hydrophobic cysteine rich 
region due to its similarity to a bona fide transmembrane domain. 
 
2. Which proteins are substrates for refolding by the synaptic chaperone CSP? 
Early efforts to discover potential clients for CSP identified multiple direct protein 
interactions including with syntaxin [32-34], VAMP [35, 36], G protein subunits [37, 
38], Rab-GDI [39], mutant huntingtin [40, 41], the α1B subunit of  N-type calcium 
channels [37, 42], the α1A subunit of P/Q type calcium channels [43] and 
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synaptotagmins [44, 45]. The observed reduction of SNAP-25 in CSPα knock out 
mice led to the identification of this protein as a potential CSPα client [46]. More 
recent work has attempted to identify novel CSPα clients by using an unbiased 
proteomic approach searching for any proteins down-regulated in the brains of CSPα 
knock-out mice. This resulted in the identification of 10 chaperones and 27 additional 
down-regulated proteins that included SNAP-25 [47]. The identification of one novel 
CSPα client, dynamin 1, was confirmed in direct binding assays and a role for CSPα 
in dynamin-mediated synaptic vesicle recycling was described in another study [48]. 
 
3. Cellular functions of CSP 
Information on the functional importance of CSP came initially from analysis of Csp 
mutants in Drosophila. The first of the papers on these mutants provided key 
evidence supporting the now accepted role of CSP as a neuroprotective chaperone 
at the synapse [49-51]. In this work it was found that loss of CSP expression resulted 
in very rapid death of adult flies, by 5 days at 22oC and within one hour at 29oC, and 
the flies showed evidence of synaptic degeneration observed by electron microscopy  
[52]. The follow-up analyses of these mutant flies focused to a large extent on 
studying the phenotype of the few adult survivors (95% of Csp null mutants die 
during development) and in particular there was an emphasis on what was seen as 
the “temperature-dependent” aspects of the phenotypes, where the flies rapidly 
became paralysed at elevated temperature [53], rather than the causes of the rapid 
neurodegeneration and death.   
Electrophysiological analysis of synaptic function in Csp mutant flies 
suggested that CSP was required for normal synchronous evoked neurotransmitter 
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release [54, 55], but this did not appear to be related to any effect on presynaptic 
calcium channel function [56]. In addition, the flies showed various defects in calcium 
handling or calcium coupling to exocytosis [57-60]. Studies on non-neuronal cells, 
examining the effects of CSP overexpression suggested a direct role for CSP in 
regulated exocytosis [61-64]. The ability of CSP to interact with its client proteins 
syntaxin or synaptotagmin in vitro was found to be modulated by its phosphorylation 
on Serine 10 [44, 65] and this phosphorylation allows interaction of CSP with 14-3-3 
protein [66]. Ser10 phosphorylation on CSP appears to be constitutive within 
neuronal tissues [67-69], although the extent of phosphorylation varies greatly 
between neighbouring GABAergic and glutamatergic synapses within the same 
region of the cerebellum [67]. The effects of CSP over-expression on the late stages 
of regulated exocytosis are modulated by its phosphorylation on Ser10 [65, 70, 71]. 
 
4. CSP and neurodegeneration 
The key neuroprotective role of CSP was apparent in the fly mutants but only rose to 
prominence in considerations of the function of the protein following analysis of 
CSPα knock-out mice. For the first few weeks of life, these mice appeared normal 
and did not show defects in neurotransmission [22], but then developed a 
progressive sensorimotor disorder, evidence of neurodegeneration in neuromuscular 
junctions and calyx synapses and died at around 8 weeks of age. These mice also 
showed extensive and rapid degeneration of retinal photoreceptors [23] and 
hippocampal GABAergic neurons were found to be differentially sensitive to the 
absence of CSPα compared to glutamatergic neurons [72]. The high sensitivity of 
GABAergic neurons was attributed to their high levels of synaptic activity, which is 
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consistent with the more rapid degeneration seen in tonically active ribbon synapses 
of photoreceptor cells compared to other retinal synapses [23]. More detailed 
analysis of the mice revealed additional defects in synaptic function including a 
reduction in the normal calcium sensitivity of the neurotransmitter release 
mechanism [73] and also an impairment of synaptic vesicle recycling at the 
neuromuscular junction [48]. These latter findings would fit with the existence of 
multiple client proteins for CSP including dynamin 1. 
The evolutionary conservation of CSP’s neuroprotective function is underlined 
by a recent study of the C. elegans CSP orthologue, which is known as DNJ-14. The 
phenotypes of dnj-14 null mutant worms show remarkable similarities to CSP 
knockout mice in that young animals are virtually indistinguishable from wild-type, 
but exhibit progressive neuronal dysfunction and neurodegeneration with increasing 
age and have a reduced lifespan [24]. It is not clear why complete loss of CSP in 
Drosophila causes ~95% embryonic lethality, whereas no major effects on fertility or 
initial viability are observed in knockout worms and mice, but perhaps this reflects 
some specific functions of CSP during fly development. Neurodegeneration in aged 
C. elegans dnj-14 mutants preferentially affects sensory neurons and indeed these 
animals exhibit severely impaired chemosensory neuron function before 
neurodegeneration becomes apparent [24]. This progression from early functional 
synaptic defects leading on to later structural alterations and neuronal death is 
reminiscent of many neurodegenerative diseases and suggests that the dnj-14 worm 
model may be useful for identifying generally neuroprotective mechanisms and 
therapies. However, the surprising observation that loss of CSP is actually 
neuroprotective in a Drosophila model of injury-induced axonal degeneration [74] 
suggests that some acute neurodegeneration models could involve distinct 
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mechanisms that may not be ameliorated by CSP’s otherwise universal 
neuroprotective function. 
A surprising finding was that the neurodegeneration and reduced life-span in 
CSPα KO mice was significantly reversed by overexpressing α-synuclein [46]. Both 
wild-type and a disease-related mutant (A30P) α-synuclein had positive effects 
although that of the wild-type protein was more marked. Conversely, the CSPα KO 
phenotype was exacerbated by knock-out of α- or β-synuclein [46]. Analysis of CSPα 
KO mice expressing the A30P mutant version of α-synuclein revealed that these 
mice show increased synaptic function consistent with a protective function even of 
this pathogenic form of α-synuclein [75]. A further important observation from the 
study of CSPα KO mice and α-synuclein overexpression was that the absence of 
CSPα resulted in a reduction in SNAP-25 levels and a corresponding reduction in the 
levels of assembled SNARE complexes [46]. The loss of SNAP-25 was not affected 
by overexpression of α-synuclein. In contrast, wild type but not A30P α-synuclein 
reversed the reduction in SNARE complexes suggesting that this may contribute, at 
least in part, to the protective effect of α-synuclein. A further link between α-
synuclein and CSPα was shown in a study examining the effects of exogenous α-
synuclein or a β-amyloid peptide on cultured hippocampal neurons where both 
treatments were observed to result in a reduction in levels of CSPα expression [76]. 
 It may seem surprising that SNAP-25 has been identified as a potential client 
for CSPα, as CSPα is primarily a synaptic vesicle protein whereas SNAP-25 is 
largely localised to the axonal plasma membrane (Figure 2). Furthermore, CSPα is 
expressed at relatively low levels (2.8 molecules per synaptic vesicle and 941 
molecules per synapse, on average) compared to the very abundant SNAP-25 
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(26,686 molecules per synapse) [77, 78]. This raises some interesting mechanistic 
questions, as presumably only SNAP-25 molecules in the immediate proximity of 
tethered/docked vesicles at the active zone would be close enough to be 
chaperoned by CSPα/Hsc70. Perhaps this forms a useful checkpoint system, 
ensuring that the energy of ATP hydrolysis by Hsc70 is only expended on priming 
SNAP-25 molecules that can form a local SNARE complex and so drive membrane 
fusion. Nevertheless, it remains unclear how CSP prevents proteasomal degradation 
of the majority of the cellular pool of SNAP-25 despite its substrate being >25-fold in 
excess and mostly localised away from the active zone where CSP binding could 
potentially occur. 
Notwithstanding these questions, detailed analysis of the CSPα knock-out 
mice has strongly suggested that SNAP-25 is the major client for CSP, that CSPα 
stimulates SNARE complex assembly and that neurodegeneration in the absence of 
CSPα can be explained by defective SNAP-25 function [79, 80]. The work of Sharma 
et al [79] showed that in the absence of CSPα SNAP-25 is selectively decreased due 
to its ubiquitination and its proteolysis in an activity-dependent manner. Moreover, 
CSPα over-expression increased SNAP-25 levels. In vitro binding experiments 
suggested that CSPα did not bind directly to SNAP-25, but did so indirectly via 
Hsc70. This is unusual as J domain proteins usually bind the client protein directly 
and then subsequently recruit Hsc70. In an additional study exploring synuclein 
function it was found that the absence of the synucleins reduced the ability of the 
SNAREs to assemble into SNARE complexes and that α-synuclein directly 
stimulated SNARE complex assembly in vitro. This required the direct binding of α-
synuclein to VAMP. These findings could explain the earlier finding [46] that over-
expression of α-synuclein compensates for the loss of CSPα and thereby SNAP-25. 
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A key question at this point was whether the effect of CSPα absence on SNAP-25 
levels or on its folding is the cause of neurodegeneration in the CSPα knock-out 
mice. One possibility was that it is not the reduction in SNAP-25 levels themselves 
that leads to synaptic dysfunction and subsequent neurodegeneration, but the 
accumulation of aberrantly folded forms of SNAP-25  that undergo abnormal protein 
interactions or that other CSPα clients were involved [81]. This issue of the link 
between SNAP-25 and neurodegeneration was further addressed leading to the 
finding that decreased SNAP-25 levels worsened the CSPα knock-out phenotype 
reducing life-span and levels of assembled SNARE complexes and exacerbated 
neurodegeneration [80]. An increase of SNAP-25 levels using lentiviral expression 
rescued the CSPα knock-out phenotype with neurodegeneration (neuronal loss) 
being reversed in brain regions over-expressing SNAP-25. These findings are 
consistent with SNAP-25 being the main CSPα client whose loss leads to 
neurodegeneration in the absence of CSPα. 
 
4. CSP and human neurodegenerative disease 
Despite the compelling evidence for an essential role of CSP in preventing 
neurodegeneration in animal models, a direct link to human disease was established 
only recently. Between 2011 and 2013, four independent research groups reported 
an association between mutations in the CSPα-encoding DNAJC5 gene and adult 
onset neuronal ceroid lipofuscinosis (ANCL), using a combination of whole exome 
sequencing, linkage analysis and candidate gene resequencing [82-85]. ANCL, also 
known as autosomal dominant Kufs’ disease and Parry disease, is a very rare 
hereditary neurodegenerative disorder. It presents with broad clinical variability, 
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although common signs include generalised epilepsy, movement disorders and 
progressive dementia. The disease has a mean age of onset of 30 years and 
progresses rapidly upon diagnosis, with death occurring on average at 45 years of 
age [85]. Pathologically, ANCL is associated with intra-neuronal inclusions of 
autofluorescent lipofuscin-like material and neurodegeneration, hence its 
classification as one of the neuronal ceroid lipofuscinoses, which is a large 
genetically heterogeneous class of neurodegenerative disorders defined by these 
two essential features [86, 87]. However, the visual system tends to be unaffected by 
neurodegeneration in ANCL, in contrast to most other NCLs that are generally 
associated with blindness [85, 86]. Given its rarity and clinical variability, ANCL is 
often misdiagnosed [83], so it is important that several independent groups identified 
the same DNAJC5 mutations in different patient groups, leaving little doubt that 
these mutations cause ANCL. 
 Interestingly, all ANCL patients studied to date harbour one of two mutations 
in the coding sequence for the cysteine string motif, resulting in either a deletion of 
leucine116 or a leucine115-arginine substitution [82-85] (see Figure 1). Given the 
known requirement of the cysteine string domain for palmitoylation [7, 9, 10] and for 
targeting to post-Golgi membranes [9], this immediately suggested that the mutant 
proteins may be inefficiently targeted to synaptic vesicles. Indeed, the original report 
by Noskova et al [82] showed that recombinant GFP-tagged CSPα mutant constructs 
were retained in an abnormal cell body localisation co-migrating with endoplasmic 
reticulum and Golgi markers, in contrast to wild type GFP-CSPα that was efficiently 
transported to the plasma membrane. Consistent with such a targeting defect, post-
mortem brain samples from ANCL patients similarly showed a large reduction in 
synaptic CSPα levels compared to controls [82]. These findings were independently 
12 
 
confirmed and extended by Greaves et al [88], who demonstrated that the ANCL 
mutations induce aggregation into SDS-resistant palmitoylated aggregates. 
Importantly, Greaves et al used a dual epitope tagging system to reveal that wild 
type CSPα can co-aggregate with mutant CSPα [88], a finding that has recently been 
confirmed [89], thereby potentially explaining the dominant effect of the mutations 
and the otherwise puzzling observation that ANCL patients lack synaptic CSPα 
protein despite carrying one wild type DNAJC5 allele.  
 Although ANCL is the only disease known to be caused by CSP mutations, 
alterations in the levels or activity of CSP could potentially impact on other 
neurodegenerative conditions given its neuroprotective function. One clue is the 
finding that CSPα can interact with mutant huntingtin containing an expanded polyQ 
domain but not the wild type protein in vitro [40]. This was confirmed in a proteomic 
study of mouse brain [41] but its relevance to the progress of Huntington’s disease is 
still to be established. In addition, it has recently been reported that expression of 
CSPα is reduced in degenerating areas of the forebrain in post-mortem samples of 
Alzheimer’s patients [90]. It appears that this is not simply a consequence of reduced 
synaptic vesicle number, as the integral synaptic membrane protein marker, 
synaptophysin, did not exhibit equivalent reduced expression. Interestingly, the 
reduction of CSPα expression is restricted to degenerating brain areas, with levels 
actually being increased in non-degenerating cerebellar tissue from the same 
patients [90]. Note, however, that heterozygous CSP KO mice, which contain half the 
normal CSP protein level, do not show any difference in susceptibility to prion 
disease in the ME7 model [91]. Nevertheless, a further connection between CSPα 
and more common forms of neurodegeneration comes from the observation that 
SNARE complex levels are reduced in post-mortem brain samples from both 
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Alzheimer’s and Parkinson’s disease patients [92]. Given the role of CSPα in 
facilitating SNARE complex assembly discussed earlier, it is tempting to speculate 
that the reduced levels of SNARE complexes are a consequence of impaired CSPα 
chaperone activity. Clearly, it is important that further studies of post-mortem tissue 
from a variety of neurodegenerative diseases are performed to establish if altered 
CSP activity and/or SNARE complex assembly represent common underlying 
features of neurodegeneration.  
 
5. Therapeutic implications 
CSP is expressed in all synapses and prevents neurodegeneration in worms, flies, 
mice and humans. It therefore appears to be a generally neuroprotective chaperone 
protein. Drugs that could either increase CSP activity or bypass the requirement for 
CSP thus represent potential therapies - not only for ANCL, but more generally for 
neurodegenerative diseases. Indeed, recent work has begun to identify compounds 
that can compensate for the lack of functional CSP in animal models. Treatment of 
CSPα knock-out mice with proteasome inhibitors was found to result in increased 
life-span and a delay in neurodegeneration [92]. This striking result is at first glance 
surprising, as one widely-proposed therapeutic strategy for protein misfolding 
disorders that lead to neurodegeneration is to increase the activity of the ubiquitin-
proteasome system that degrades the misfolded protein(s). It might be expected, 
therefore, that proteasome inhibition would exacerbate neurodegeneration in CSPα 
knock-out mice. The fact that the reverse is true was attributed to an observed 
increase in SNAP-25 levels and in assembled SNARE complexes through 
prevention of SNAP-25 degradation by the proteasome [92]. Furthermore, Sharma et 
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al showed that the reduced levels of assembled SNARE complexes that ultimately 
cause neurodegeneration in CSPα knock-out mice are also evident in post-mortem 
brain samples from Alzheimer’s and Parkinson’s disease patients [92]. Proteasome 
inhibitors may therefore have therapeutic applications for these common 
neurodegenerative diseases as well as for ANCL. 
 A recent chemical screen revealed that resveratrol can rescue the short 
lifespan, chemosensory impairment and neurodegeneration phenotypes of C. 
elegans dnj-14 null mutants [24]. Resveratrol is a plant-derived polyphenolic 
compound found in various foodstuffs, notably red wine, which has well-documented 
cardioprotective, anti-inflammatory, anti-tumour and neuroprotective properties [93]. 
Its mechanism of action is the subject of considerable debate, although most 
attention has focused on resveratrol’s ability to activate the Sirtuin class of NAD+-
dependent histone deacetylases, notably SIRT1. However, rescue of the dnj-14 
phenotypes by resveratrol was unaffected by deletion of the worm SIRT1 orthologue, 
sir-2.1, suggesting a Sirtuin-independent mechanism of action. It has been 
suggested that resveratrol is a competitive inhibitor of cAMP phosphodiesterases 
[94]. This is consistent with the observation that rolipram (a structurally unrelated 
cAMP phosphodiesterase inhibitor with neuroprotective properties [95, 96]) similarly 
rescued dnj-14 phenotypes (Figure 3) [24]. Furthermore, forskolin, which increases 
cAMP levels via activation of adenylate cyclase rather than phosphodiesterase 
inhibition, ameliorates the neuromuscular transmission defects in CSPα knock-out 
mice [48]. It is tempting to speculate that increased cAMP signalling activates 
alternative CSP-independent pathways that facilitate SNARE complex formation, 
thereby compensating for the lack of CSP in these animal models. Indeed, 
phosphorylation of SNAP-25 and other synaptic exocytosis proteins by cAMP-
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dependent protein kinase is known to increase SNARE-dependent 
neurotransmission [97, 98]. Alternatively, it may be that cAMP acts via longer term 
changes in gene expression mediated by neuroprotective transcription factors such 
as cAMP response element binding protein (CREB) [99]. Given the recent 
observations of reduced levels of CSP [90] and of SNARE complexes [92] in 
Alzheimer’s brain samples, this may be relevant to the reported therapeutic effects of 
rolipram [95] and resveratrol [100] in rodent Alzheimer’s models.  
 
6. Conclusions 
Despite being discovered over 20 years ago, interest in CSP has increased greatly in 
recent years as a result of compelling evidence that it provides a universal 
neuroprotective role at synapses from worms to humans. The major mechanism by 
which CSP prevents neurodegeneration appears to be maintaining the conformation 
of SNAP-25 and thereby facilitating correct SNARE complex formation. However, we 
currently lack a molecular level description of how CSP and Hsc70 interact with 
SNAP-25, how this alters SNAP-25’s conformation to facilitate SNARE complex 
formation, and how this interaction (which presumably can only occur in close 
proximity to the very small number of docked synaptic vesicles at the active zone) 
manages to prevent global degradation of SNAP-25 that mainly localises away from 
this region. In addition it seems likely that other client proteins, including dynamin, 
are also involved, so future genetic and proteomic studies may  illuminate such 
SNAP-25-independent functions of CSP. To date, mutations in the DNAJC5 gene 
encoding CSPα have only been associated with ANCL, but given the alterations in 
CSP and SNARE complex levels in Alzheimer’s disease, future human genetic 
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studies may well reveal additional mutations/polymorphisms associated with other 
more common neurodegenerative disorders. Finally, the few studies reported so far 
demonstrate that it is possible to compensate for the lack of CSP with small 
molecules – further work in this area may enable translation of the basic research on 
CSP performed over the last 20 years into novel therapies for neurodegeneration. 
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Figure legends 
Figure 1: Domain structure of human CSPα. The locations of the Serine10 
phosphorylation site, the HPD motif in the J domain, and the cysteine-rich region of 
the protein are indicated. The leucine residues mutated in ANCL patients are 
highlighted by asterisks. 
 
Figure 2: Chaperoning of SNAP-25 by CSP and Hsc70 at the synapse. A typical 
synaptic vesicle containing approximately three molecules of CSP [77] is 
represented. Binding of Hsc70 to SNAP-25 is thought to recruit CSP, thereby altering 
the conformation of SNAP-25, facilitating its entry onto the SNARE complex that 
drives membrane fusion. Direct binding is indicated by double-headed arrows. 
Structures of SNAP-25 (3IPD), and hsc70/DnaK (2KHO) were obtained from the 
Brookhaven protein data bank. The CSP structure prediction was generated by I-
TASSER. Residues involved in Hsc70 binding (HPD motif, blue), synaptotagmin 
binding (E93, yellow), and the serine-10 phosphorylation site (green) are highlighted 
as spheres. All structures were rendered using UCSF chimera.   
 
Figure 3: Resveratrol and rolipram rescue the short lifespan of C. elegans dnj-
14 mutants. Lifespan assays were performed on dnj-14(tm3223) strains, which 
contain a large deletion in the worm orthologue of CSP, in the presence and 
absence of drugs; and also on the corresponding wild type strain (Bristol N2).  
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